Table 1 Participant characteristics, N = 108

Variable

All

(n = 39)

(n = 69)

Age (years)

Mean (SD)

Mean

16.7 (2.0)

16.5 (1.8)

16.9 (2.2)

n (Percent)

Race/Ethnicity

White

82 (76)

26 (66)

56 (81)

Black

11 (10)

5 (13)

6 (9)

Latinx

9 (8)

5 (13)

4 (6)

Asian

3 (3)

2 (5)

1 (1)

American Indian/Alaska Native

1 (1)

1 (3)

0

Prefer not to answer

2 (2)

0

2 (3)

Rheumatic diagnosis

Juvenile idiopathic arthritis

56 (52)

19 (49)

37 (54)

Systemic lupus erythematosus

17 (16)

8 (20)

9 (13)

Primary Raynaud’s

6 (6)

1 (3)

5 (7)

Juvenile dermatomyositis

5 (5)

2 (5)

3 (4)

Scleroderma

5 (5)

3 (8)

2 (3)

Vasculitis

5 (5)

1 (3)

4 (6)

Idiopathic uveitis

4 (4)

2 (5)

2 (3)

MCTD/UCTD^a

4 (4)

2 (5)

2 (3)

Sjogrens syndrome

3 (3)

0

3 (4)

Chronic recurrent multifocal osteomyelitis

2 (2)

1 (3)

1 (1)

Antiphospholipid antibody syndrome

1 (1)

0

1 (1)

Current Teratogen Use

39 (36)

-

-

Methotrexate

28 (26)

28 (72)

-

Mycophenolate

11 (10)

11 (28)

-

ACE inhibitor

3 (3)

3 (8)

-

Cyclophosphamide

1 (1)

1 (3)

-

Leflunomide

1 (1)

1 (3)

-

Ever sex

Yes

26 (24)

6 (15)

20 (29)

No

77 (71)

31 (80)

46 (67)

Prefer not to answer

5 (5)

2 (5)

3 (4)

Ever vaginal sex

23 (21)

5/6 (83)

18/20 (90)

Currently sexually active

15 (14)

5/6 (83)

10/20 (50)

Current LARC use^b

5 (5)

2 (5)

3 (4)

Among sexually experienced youth

-

1/6 (17)

2/20 (10)

Current effective hormonal contraceptive use^c

26 (24)

6 (15)

20 (29)

Among sexually experienced youth

-

3/6 (50)

11/20 (55)

Current condom use without hormonal contraception

5 (5)

4 (10)

1 (1)

Among sexually experienced youth

-

2/6 (33)

1/20 (5)

Ever Pregnant

Yes

1 (1)

Prefer not to answer

1 (1)